GSK, Boehringer Ingelheim Discussing Co-Packaged Combivir/Viramune

The companies have signed a “letter of intent” and are talking to FDA about NDA submission requirements. The agreement may test how quickly the agency can approve co-packaged HIV therapies, and how easy it is for manufacturers to negotiate deals.